ImmunityBio stock holds gains as analysts see strong ANKTIVA growth

ImmunityBio stock is consolidating recent gains as analysts highlight the potential of ANKTIVA, projecting robust revenue growth into 2026 while biotech peers remain volatile.

ImmunityBio stock (ISIN US45258J1025) has been consolidating its recent rally as of September 1, 2026, after a sharp multi-month advance that left the biotech name among the stronger performers in its peer group, according to data from a retail-investor news overview that highlighted a 240 percent gain for the shares over the past year and underscored renewed interest in oncology-focused small and mid caps.

Biotech focus shifts to ANKTIVA ramp

For ImmunityBio, the next leg of the story is increasingly tied to ANKTIVA, its immunotherapy for non-muscle-invasive bladder cancer, and the expectations that surround the product ramp over the coming quarters. According to an analyst outlook summarized by an Investing.com report on September 1, 2026, ImmunityBio is due to report Phase III QUILT-2.005 data in the second half of 2026 on approximately 566 BCG-naive carcinoma in situ non-muscle-invasive bladder cancer patients, a data set viewed as relevant for potential label expansion in 2027.

The same analyst summary notes that ANKTIVA already has a PDUFA decision date set for January 6, 2027, for BCG-unresponsive papillary non-muscle-invasive bladder cancer, anchoring the regulatory timetable that many biotech investors are now tracking as a key catalyst. In that context, the analysts project ANKTIVA revenue to grow by 85 percent in 2026 to reach 210 million USD, suggesting that the product could meaningfully scale from its initial launch base and support a higher revenue mix for ImmunityBio if execution stays on track.

Analyst projections support ImmunityBio stock narrative

The quantitative projections around ANKTIVA illustrate why some market participants see upside in ImmunityBio stock despite the already strong performance over the past twelve months. An 85 percent increase in ANKTIVA revenue in 2026, from a prior-year level implied at roughly 113 million USD to a projected 210 million USD, would mark one of the steeper growth curves among commercial-stage oncology assets in the small to mid cap cohort and would provide ImmunityBio with a more predictable top-line base compared with earlier years in which the company was still largely pre-revenue.

For equity investors, such a step change in product revenue can be a key input for valuation models because it improves visibility on cash flows and can help justify both the recent 240 percent share price increase over the past year and the current analyst price target of 12 USD per share cited in the Investing.com summary as the benchmark for upside. If the stock were to trade at that target, it would still leave room relative to the present market level, although the exact spread depends on the latest intraday quotation on the Nasdaq given the usual day-to-day volatility in biotech names.

ImmunityBio pipeline and product focus

Beyond ANKTIVA, ImmunityBio positions itself as an immunotherapy company with a pipeline that targets various tumor types using both cytokine based and cell based approaches. While ANKTIVA currently carries the bulk of near term commercial expectations and the clearest revenue targets into 2026, the broader development portfolio provides additional optionality for longer term investors who weigh pipeline breadth and probability of success in parallel with near term sales ramps when evaluating biotech stocks.

ImmunityBio stock and investor view

With the ANKTIVA PDUFA date scheduled for January 6, 2027 and Phase III QUILT-2.005 data expected in the second half of 2026, ImmunityBio stock remains closely tied to regulatory and clinical milestones that can sway sentiment quickly. As of the latest available quotations around the start of September 2026, the shares reflect a strong year-on-year gain of 240 percent, while analyst projections of 85 percent ANKTIVA revenue growth to 210 million USD in 2026 provide a tangible benchmark against which investors can gauge execution over the coming quarters.

ImmunityBio stock at a glance

• Company: ImmunityBio Inc.
• ISIN: US45258J1025
• Ticker: IBRX
• Trading venue: NASDAQ
• Sector / Industry: Biotechnology / Biopharmaceuticals
• Index membership: Not part of a major headline index such as the S&P 500 or Nasdaq 100